The table below shows CytomX Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$10.26M
$5.96M
$18.66M
$50.92M
$33.43M
$25.11M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$19.24M
$15.30M
$13.32M
$18.87M
$21.37M
$25.17M
SG&A
CTMX annual revenue (10-K history)
CytomX Therapeutics, Inc. reported annual revenue of $76.20M for fiscal year 2025. That is down 44.8% from $138.10M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $15.04M (FY 2016) to $76.20M. Figures come from the company's audited annual reports as filed with the SEC.